| Outcome Measures: |
Primary: Change From Baseline in HbA1c, HbA1c is the glycosylated fraction of haemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Change from baseline in HbA1c was analysed by mixed model repeated measures (MMRM) including fixed effects of treatment, stratification factors (country, BMI group \[\> 30 or ≤ 30\], sulfonylureas use at study entry), visit and treatment by visit interaction and baseline HbA1c as the covariate., Baseline, Week 32 | Secondary: Change From Baseline in HbA1c Compared to Insulin Degludec, HbA1c is the glycosylated fraction of haemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Change from baseline in HbA1c was analysed by MMRM including fixed effects of treatment, stratification factors (country, BMI group \[\> 30 or ≤ 30\], sulfonylureas use at study entry), visit and treatment by visit interaction, and baseline HbA1c as the covariate., Baseline, Week 32|Change From Baseline in Fasting Glucose, Change from baseline in fasting glucose was analysed by MMRM including fixed effects of treatment, stratification factors (country, BMI group \[\> 30 or ≤ 30\], sulfonylureas use at study entry, HbA1c strata \[\<8.5% or ≥8.5%\]), visit and treatment by visit interaction, and baseline fasting glucose as the covariate., Baseline, Week 32|Change From Baseline in Insulin Dose (LY3209590), The baseline for both LY3209590 arms was the first regular weekly dose at Week 1., Week 1, Week 32|Change From Baseline in Insulin Dose (Insulin Degludec), Change from Baseline in Insulin Dose for Insulin Degludec arm was reported., Baseline, Week 32|Rate of Total Documented Symptomatic Hypoglycemia, The hypoglycemia events were defined by participant reported events with glucose ≤54 mg/dL (3.0 millimole per liter (mmol/L)). Relative Rate was calculated based on Group Mean. Group Mean was estimated by first taking the inverse link function on individual patient covariates, then averaging over all participants., Baseline through week 32|Change From Baseline in Body Weight, Change from baseline in body weight was analysed by MMRM including fixed effects of treatment, visit and treatment by visit interaction, and baseline body weight as the covariate., Baseline, Week 32|Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3209590, PK: AUC of LY3209590 was reported for LY3209590 Algorithm 1 and LY3209590 Algorithm 2 arms. AUC was calculated for individual participants using the participant's Week 32 LY3209590 dose amount and the participant's estimated clearance value., Week 32
|
| Locations: |
Central Research Associates, Inc., Birmingham, Alabama, 35205, United States|Arkansas Clinical Research, Little Rock, Arkansas, 72205, United States|John Muir Physician Network Clinical Research Center, Concord, California, 94520, United States|AMCR Institute INC, Escondido, California, 92025, United States|Valley Endocrine, Fresno, Fresno, California, 93720, United States|Marin Endocrine Associates, Greenbrae, California, 94904, United States|National Research Institute, Huntington Park, California, 90255, United States|First Valley Medical Group, Lancaster, California, 93534, United States|National Research Institute, Los Angeles, California, 90057, United States|University Clinical Investigators, Inc., Tustin, California, 92780, United States|Chase Medical Research, LLC, Waterbury, Connecticut, 06708, United States|ALL Medical Research, LLC, Cooper City, Florida, 33024, United States|Suncoast Clinical Research, New Port Richey, Florida, 34652, United States|Metabolic Research Institute Inc., West Palm Beach, Florida, 33401, United States|East West Medical Institute, Honolulu, Hawaii, 96814, United States|Elite Clinical Trials LLLP, Blackfoot, Idaho, 83221, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, 83404, United States|Iderc, P.L.C., West Des Moines, Iowa, 50265, United States|Cotton O'Neil Diabetes and Endocrinology Center, Topeka, Kansas, 66606, United States|Endocrine and Metabolic Consultants, Rockville, Maryland, 20852, United States|NECCR PrimaCare Research, LLC, Fall River, Massachusetts, 02721, United States|Palm Research Center, Las Vegas, Nevada, 89128, United States|Palm Research Center, Las Vegas, Nevada, 89148, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, 03063, United States|Metrolina Internal Medicine, P.A., Charlotte, North Carolina, 28207, United States|Intend Research, Norman, Oklahoma, 73069, United States|The Corvallis Clinic P.C., Corvallis, Oregon, 97330, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|Preferred Primary Care Physicians - Jacob Murphy Lane, Uniontown, Pennsylvania, 15401, United States|Internal Medicine Associates of Anderson, Anderson, South Carolina, 29621, United States|The Research Center of the Upstate, Mauldin, South Carolina, 29662, United States|Texas Diabetes and Endocrinology, Austin, Texas, 78731-4309, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, 75230, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, 78229, United States|Manassas Clinical Research Center, Manassas, Virginia, 20110, United States|Rainier Clinical Research Center, Renton, Washington, 98057, United States|Confluence Health Clinical Research Department, Wenatchee, Washington, 98801, United States|Hospital Universitario UANL, Monterrey, Nuevo León, 64460, Mexico|Investigacion en Salud y Metabolismo S.C, Chihuahua, 31217, Mexico|Advanced Clinical Research, LLC, Bayamon, 00961, Puerto Rico|Manati Center for Clinical Research Inc, Manati, 00674, Puerto Rico|GCM Medical Group PSC, San Juan, 00917, Puerto Rico|Martha Gomez Cuellar M.D., San Juan, 00921, Puerto Rico|Centro de Endocrinologia del Este, Yabucoa, 00767, Puerto Rico
|
